Benefit of high-dose daunorubicin in AML induction extends across cytogenetic and molecular groups
Marlise R. Luskin(Dana-Farber Cancer Institute), Selina M. Luger(University of Pennsylvania), Omar Abdel‐Wahab(Memorial Sloan Kettering Cancer Center), Ross L. Levine(Memorial Sloan Kettering Cancer Center), Hillard M. Lazarus(University Hospitals of Cleveland), Janis Racevskis(Montefiore Medical Center), John M. Bennett(University of Rochester Medical Center), Jacob M. Rowe(Technion – Israel Institute of Technology), Rhett P. Ketterling(Mayo Clinic in Arizona), Elisabeth Paietta(Montefiore Medical Center), Mark R. Litzow(Mayo Clinic in Arizona), Jay P. Patel(Memorial Sloan Kettering Cancer Center), Zhuoxin Sun(Dana-Farber Cancer Institute), Martin S. Tallman(Memorial Sloan Kettering Cancer Center), Ju-Whei Lee(American College of Radiology), Hugo F. Fernández(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa)
Cited by 128
Related Papers
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
|Blood|2016|5.9k
The landscape of somatic copy-number alteration across human cancers
|Nature|2010|4.1k